TF
ARQT icon

Trek Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Trek Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,605
Closed -$540K – 481
2025
Q4 		$540K Buy
+18,605
New +$476K 0.03% 290
2025
Q3 		– Sell
-24,970
Closed -$350K – 439
2025
Q2 		$350K Buy
+24,970
New +$350K 0.02% 315

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trek Financial's ARQT Position: Q1 2026 in Review

Trek Financial sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 18,605 shares — an estimated $540K sold.

Trek Financial first reported a position in ARQT in Q2 2025 and held it in 2 quarters. The position peaked at $540K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Trek Financial reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Trek Financial sold 18,605 Arcutis Biotherapeutics shares in Q1 2026, an estimated $540K.
  • Trek Financial first reported a position in Arcutis Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • Trek Financial's Arcutis Biotherapeutics position peaked at $540K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Trek Financial's 13F filing for Q1 2026, filed 13 May 2026.